Neuromuscular Agents - Administration & dosage
Research News and Information

Sunday, November 22, 2009

When drugs disappear from the patient: elimination of intravenous medication by hemodiafiltration.

30 Oct 2009 Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF). Increasing doses of catecholamines, sedatives, and muscle relaxants ... Read more...

Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia.

30 Oct 2009 OBJECTIVE: The aim of this pilot study was to examine changes in different aspects of impairment, including spasticity in the upper limbs, of hemiplegic children following botulinum toxin type A intervention. Progress was assessed using standard ... Read more...

The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections.

29 Sep 2009 BACKGROUND: Palmar hyperhidrosis is an uncomfortable condition that can severely affect a patient's quality of life. Injections of botulinum toxin have proven to be an efficient treatment modality, however the pain associated with palmar injections ... Read more...

Latest indexed articles for 'Neuromuscular Agents - Administration & dosage'

These are the very latest articles for this heading:

• When drugs disappear from the patient: elimination of intravenous medication by hemodiafiltration. 30 Oct 2009
• Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia. 30 Oct 2009
• The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections. 29 Sep 2009
• A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. 29 Sep 2009
• Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. 29 Sep 2009
• The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? 11 Aug 2009
• Is active sweating during heat acclimation required for improvements in peripheral sweat gland function? 3 Aug 2009
• [Local botulinum neurotoxin A therapy in tardive lingual dyskinesia] 30 Jul 2009
• Treatment of superior limbic keratoconjunctivitis with a large-diameter contact lens and Botulium Toxin A. 30 Jul 2009
• A placebo-controlled surgical trial of the treatment of migraine headaches. 30 Jul 2009
• Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. 18 Jul 2009
• [Comparison of non-invasive and invasive techniques in the treatment of patients with myofascial pain syndrome.] 29 Jun 2009
• The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study. 29 Jun 2009
• Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? 29 Jun 2009
• Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. 29 Jun 2009
• Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? 29 Jun 2009
• Rat Achilles tendon healing: mechanical loading and gene expression. 16 Jun 2009
• Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. 16 Jun 2009
• Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. 30 May 2009
• Effects of botulinum A toxin injection on the extraocular muscle fiber layers: comparison between subtenon injection and intramuscular injection. 29 May 2009

See a longer list of these articles.

Technical information about 'Neuromuscular Agents'

Definition: Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

Registry Number: 0

Descriptor UI: D009465

Alternative terms: Neuromuscular Agents; Agents, Neuromuscular; Skeletal Muscle Relaxants; Muscle Relaxants, Skeletal; Relaxants, Skeletal Muscle;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.663.700;

Online Note: use MUSCLE RELAXANTS, CENTRAL to search SKELETAL MUSCLE RELAXANTS 1977-94

History Note: 95; was NON MESH 1974-94; SKELETAL MUSCLE RELAXANTS was see MUSCLE RELAXANTS, CENTRAL 1977-94

Technical Notes: GEN or unspecified; prefer specifics; consider also NEUROMUSCULAR JUNCTION /drug eff & MUSCLES, SKELETAL /drug eff